Regeneron Pharmaceuticals, Inc. REGN revealed data from Phase 3 trials in adults with moderate-to-severe cat or birch allergies on Monday. Both trials met their respective primary and key secondary endpoints.REGN is feeling the pressure from bearish momentum. Get the market research here.Allergen-blocking antibody treatment in Cat-allergen “Ocular Challenge” TrialREGN1908 and REGN1909 are two fully human monoclonal antibodies (mAbs) targeting and blocking FelD1.In the Phase 3 trial, cat-allergic participant ...